Program
Everolimus
Also written as “everolimus”, “RAD001” and “Everolimus (RAD001)”.
Its studies are mostly in Breast Neoplasms · Carcinoma, Renal Cell · Tuberous Sclerosis · Carcinoma, Non-Small-Cell Lung · Neuroendocrine Tumors, led by 4 companies.
Drug pageEverolimus: every studyAll 618 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 1201 open or running | phase 4since Sep 8, 2005 | Oct 6, 2004 | Feb 26, 2027phase 3 · NCT02962414 |
| Chong Kun Dang Pharmaceutical | 21 open or running | phase 4since Apr 29, 2021 | Apr 29, 2021 | Dec 2030phase 4 · NCT06942156 |
| iOMEDICOits history only | 20 open or running | phase 4since Dec 23, 2010 | Dec 23, 2010 | none ahead |
| Chiesi Farmaceuticiits history only | 10 open or running | phase 2since Oct 28, 2016 | Oct 28, 2016 | none ahead |
Also a collaborator on its studies: Merck, Pfizer, Cromsource and Roche Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 29, 2021First study: phase 4 study in Liver TransplantFirst studyNCT04867720 · 112 enrolled · Korea, Republic of
- Apr 11, 2025Phase 4 study in Heart TransplantNCT06942156 · 140 planned · Korea, Republic of
Ahead
- Dec 2030Primary completion: phase 4 study in Heart TransplantNCT06942156
TargetBeta
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule
Other programs on FKBP1A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tacrolimusrule | Astellas Pharma | phase 4 | 182 |
Studies
All 2 Chong Kun Dang Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06942156Heart Transplant · Korea, Republic of | 4 | Not yet recruiting | Dec 2030 | 140 |
| NCT04867720Liver Transplant · Korea, Republic of | 4 | UNKNOWN | Oct 10, 2022 | 112 |
How it is read
Names in the registry
- “Everolimus”, 64 entries
- “everolimus”, 16 entries
- “RAD001”, 16 entries
- “Everolimus (RAD001)”, 15 entries
- “Everolimus (reduced tacrolimus)”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 17 studies
- Carcinoma, Renal Cell, 12 studies
- Tuberous Sclerosis, 5 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Neuroendocrine Tumors, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.